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ABSTRACT
Objectives: The family members of patients with
rheumatoid arthritis (RA) are at increased risk of
developing RA and are potential candidates for
predictive testing. This study explored the perceptions
of first-degree relatives of people with RA about being
at risk of RA and engaging in predictive testing.
Methods: 34 first-degree relatives (siblings and
offspring) of patients with RA from the UK, Germany and
Austria participated in semistructured interviews about
their perceptions of RA risk and the prospect of
predictive testing. Interviews were audio-recorded,
transcribed verbatim and analysed using thematic
analysis.
Results: First-degree relatives were aware of their
susceptibility to RA, but were unsure of the extent of their
risk. When considering their future risk, some relatives
were concerned about the potential impact that RA would
have on their lives. Relatives were concerned that
knowing their actual risk would increase their anxiety and
would affect decisions about their future. Also, relatives
were concerned about the levels of uncertainty
associated with predictive testing. Those in favour of
knowing their future risk felt that they would need
additional support to understand the risk information and
cope with the emotional impact of this information.
Conclusions: Identifying individuals at risk of RA may
allow targeted interventions to reduce the risk and
consequence of future disease; however, relatives have
concerns about predictive testing and risk information.
The development of strategies to quantify and
communicate risk needs to take these views into account
and incorporate approaches to mitigate concerns and
minimise the psychological impact of risk information.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic
destructive polyarthritis. It affects ∼1% of the
population1 and typically manifests in the
fourth and ﬁfth decades of life.2–4 Delays in
diagnosis and treatment of RA are common
and are associated with worse outcomes.5–8
Recently, an increased research effort has
been directed towards the ‘at-risk’ phases of
RA, prior to the development of clinical signs
of joint swelling, to identify those at risk of
developing RA and to reduce this risk through
the modiﬁcation of environmental risk factors
and pharmacological intervention.9–11
Genetic factors contribute signiﬁcantly to
the risk of RA.12 For seropositive RA, at least
half of the risk is conferred by genetic risk
factors;13 recent large genetic studies have
identiﬁed over 100 susceptibility loci.14 15
Population-based epidemiological studies
have shown that having a family history of RA
increases the risk of RA by approximately
Strengths and limitations of this study
▪ This study used inductive qualitative interviews
to explore perceptions about risk and predictive
testing in the first-degree relatives of people with
rheumatoid arthritis.
▪ This study identified positive and negative per-
spectives surrounding predictive testing, and
why some people at risk may not wish to be
tested.
▪ Further research is needed to quantify the
numbers of people at risk holding negative per-
ceptions about predictive testing and to identify
the behavioural implications of these beliefs.
▪ Communicating risk information to relatives
effectively while reducing the psychological
burden associated with this information should
be the focus of future interventional research.
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three to ﬁve times,16–18 with the risk being higher in
ﬁrst-degree relatives than second-degree relatives.17
Furthermore, a range of environmental and lifestyle risk
factors including occupational exposure to pollutants,19
body mass index,20 periodontitis,21 reproductive
factors,22 smoking23 and dietary factors24–26 contribute
to the increased risk of developing RA. Some of these
environmental risk factors may interact mechanistically
with genetic risk factors to increase the risk of RA,27 and
others may have familial associations, thus contributing
to the familial aggregation of RA.28 29
Individuals with genetic and environmental risk
factors for RA may progress through a phase associated
with the development of systemic autoimmunity (eg, the
development of autoantibodies such as rheumatoid
factor,30 31 anticitrullinated protein/peptide antibodies
and anticarbamylated protein antibodies32) before the
clinical symptoms and signs of RA manifest.9 It remains
unclear whether there are changes detectable within the
synovium during the phase of autoantibody positivity
prior to the development of joint swelling.33 34
Together these data suggest that information related
to genotype, environmental exposures and measures of
autoimmunity and inﬂammation may be used to predict
RA development in individuals who have not yet devel-
oped clinical disease. A potential target population for
such testing, with a view to risk stratiﬁcation and inter-
vention to modulate risk, are the ﬁrst-degree relatives of
individuals with RA. Indeed, a number of ongoing pro-
spective studies are recruiting the ﬁrst-degree relatives of
patients with RA to study disease mechanisms driving
the switch to RA,35 to develop predictive algorithms for
RA and to test interventions to reduce RA risk.36 While
considerable research effort is thus focused on the ﬁrst-
degree relatives of patients with RA, and a qualitative
study has gathered data relating to their views of pre-
ventive strategies,37 little is known about how such indivi-
duals view issues related to their susceptibility to and risk
of developing RA, and how willing they would be to be
assessed and tested to have this risk quantiﬁed. The
present qualitative study addresses these issues.
PROCEDURE
Eligible participants were the ﬁrst-degree relatives (off-
spring and siblings) of people with RA. Participants were
required to be at least 18 years of age and without a
diagnosis of inﬂammatory joint disease.
Patients with RA were approached during routine sec-
ondary care clinics in Birmingham (UK), Erlangen
(Germany) and Vienna (Austria) and were given a letter
to pass on to a ﬁrst-degree relative of their choosing
inviting them to participate in an interview about risk
and predictive testing for RA. Participants were recruited
between October 2014 and October 2015. It was
explained to patients that it was entirely at their discre-
tion whether to pass on the invitation letter. All research
participants (ie, the participating ﬁrst-degree relatives)
gave written informed consent prior to interview.
The semistructured interviews were guided by an inter-
view schedule which was informed by a review of the quali-
tative literature exploring perceptions of risk and testing
in those at risk of developing a chronic disease.38 39 The
interviews aimed to assess personal perceptions of risk;
therefore, one-to-one interviews were conducted. In add-
ition, an international multidisciplinary team of healthcare
professionals, patient research partners and researchers
working on the EuroTEAM project (http://www.
team-arthritis.eu) reviewed and redrafted the interview
schedule (see box 1 for sample questions from the ﬁnal
interview schedule).
One-to-one interviews were conducted at local hospi-
tals or by telephone (for those participants who had dif-
ﬁculty in attending the hospital for a face-to-face
interview). Interviews lasted between 30 and 90 min and
were digitally audio-recorded. In the UK, participants
who wanted further information about arthritis were
advised to contact Arthritis Research UK, the National
Rheumatoid Arthritis Society or the local hospital’s
Patient Advice and Liaison Service. Participants in
Austria and Germany were advised to contact the local
rheumatology outpatient clinic.
The interviews were transcribed verbatim. Interviews
conducted in German were translated into English fol-
lowing transcription. Transcripts were anonymised and
analysed centrally in Birmingham, UK, by RJS.
Analysis procedure
Data collection and analysis were carried out in parallel
to assess when thematic saturation of major developing
Box 1 Sample interview schedule for those at risk of
developing rheumatoid arthritis (RA)
▸ Tell me what you know about RA?
▸ PROMPTS: What do you think the causes of RA could be?
What do you think the risks factors for RA are? Tell me about
how serious you think RA is? How would you know you had
RA, for example, what symptoms would you expect? What
would be the impact of RA on your life? Do you think you
would be able to control RA yourself? Do you think there are
treatments available that would effectively treat RA?
▸ Do you ever worry about the possibility of developing RA in
the future?
▸ What would you think if you were told that you could have a
test that would tell you how likely you were to develop RA?
▸ PROMPTS: What sort of information should this test give
you? When do you think would be the right time to get this
information? How would you feel about the idea of having a
test that would tell you your chance of developing RA in the
future? In what ways do you think it would be helpful for you
to know your chances of developing RA?
▸ What would your concerns be if you knew what your risk of
developing RA was?
▸ What kind of tests do you think people might be able to do to
work out whether or not you might develop RA (test that are
available now and tests that might become available in the
future)?
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themes had been achieved. The data were analysed using
a thematic approach40 facilitated by NVivo (a qualitative
software programme) (NVivo qualitative data analysis
software; QSR International Pty Version. 8 (2008)).
Transcripts were subjected to line-by-line coding by RJS.
Patient research partners blind coded three transcripts to
develop reliable and inclusive themes informed by mul-
tiple perspectives. Discussion of the coding framework
took place between researchers and patient research part-
ners. Coding categories that lacked concordance were
discussed and absorbed into the coding framework. The
initial codes were then grouped into the most noteworthy
and frequently occurring categories. The core themes
extracted and presented here focus on perceptions of
ﬁrst-degree relatives about their personal risk of RA and
their views on being tested.
RESULTS
Thirty-four ﬁrst-degree relatives of patients with RA par-
ticipated, 24 from the UK, 3 from Germany and 7 from
Austria. Six participants were siblings of a patient with
RA, 26 were the adult offspring of a patient with RA and
2 participants had a sibling and a parent with RA.
Participants were aged between 23 and 67 years (mean
39 years) and 26 (76%) were women (see table 1 for par-
ticipant characteristics). Quotations are presented in
tables 2–5 and are referred to in the text using ‘Q’ fol-
lowed by the quotation code.
Understanding of family history and genetic factors as risk
factors for RA
The ﬁrst-degree relatives of people with RA understood
that there was a hereditary component to RA (Q1), and
often used the word ‘genetic’ to describe the cause of
their increased risk (Q2). First-degree relatives (from
here on referred to as ‘relatives’) recognised that they
were more susceptible to developing RA than second-
degree relatives (Q3). Interestingly, some felt that they
were more susceptible to developing RA than other ﬁrst-
degree relatives because they appeared to follow other
patterns of illness displayed by their relative with RA
(Q4). Additional biological factors, such as being
women and some environmental factors, were also
described as playing a role in the development of RA
(Q2 and Q5).
When considering their perceived personal suscepti-
bility, relatives reported that there were aspects of famil-
ial risk, particularly genetic susceptibility, which they
found difﬁcult to understand. One relative felt that
effectively communicating an understanding of genetic
risk to the public was extremely challenging (Q6).
Others felt that they needed more information about
their level of risk as a relative and the speciﬁc role that
genes associated with RA played in this risk (Q7).
When considering their susceptibility to RA, relatives
voiced their concerns about the future, and how being
at risk of developing RA was a worry for them. Those
who had considered their personal susceptibility to RA
described being fearful of what they may uncover if they
were to have their risk quantiﬁed. For some, the pros-
pect of living with RA would entail great amounts of
uncertainty (Q8). For many, having witnessed the
impact of RA on their sibling/parent heightened the
worry they felt in relation to the possibility of developing
RA themselves in the future (Q9). Interestingly, a small
number of relatives had experienced joint-related symp-
toms but had not yet sought medical advice, being
fearful of the potential outcome (Q10).
Personal considerations of RA risk and communication
about risk within families
Relatives discussed knowing little about RA or its risk
factors, feeling that they had been ‘shielded’ or ‘pro-
tected’ from this knowledge by their sibling/parent
(Q11). Also, relatives described how they rarely dis-
cussed RA within their family unit, and in some cases,
the invitation to participate in this study was the ﬁrst
time that the opportunity to discuss RA, and its risk had
emerged (Q12). For one relative, receiving the invitation
to take part in this study facilitated the ﬁrst conversation
he had had with his father about RA (Q13). Another
described how his mother had had some concerns
about him taking part in this study, because of the worry
which discussing issues surrounding risk and predictive
testing may cause (Q14). One relative described how
her brother had been asked to take part in this study,
but ignored the request; her mother had then
approached her and encouraged her to participate
(Q15). This relative suggested that it was her attitude
towards health which set her apart from her brother.
Most relatives had not fully considered issues related
to their personal susceptibility to RA prior to being
approached to take part in this study (Q16). Some rela-
tives indicated that taking part in this study had been a
positive experience for them and had provided them
with much needed knowledge, a chance for reﬂection
on their risk and a greater understanding of RA and
how it affected their sibling/parent (Q17). However,
others described how they would prefer to avoid consid-
ering their personal risk of RA to avoid experiencing
worry or anxiety about the future (Q18).
Perceptions surrounding the use of predictive tests:
positive perspectives
Most relatives were in favour of the basic principle
behind predictive testing—identifying those at risk and
quantifying the level of risk (Q19). It was also felt that
the information gained from predictive testing could be
acted on to reduce the future risk of developing RA
(Q20). In particular, relatives recognised the importance
of early intervention, and they were aware that testing
could put them ‘on alert’ for the early symptoms of RA
(Q21) or suggested that they might be able to take pre-
ventive treatment (Q22). Many relatives felt that it was
important to know that they were at risk and that
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Table 1 Details of first-degree relatives of patients with RA who participated in the interviews
Participant
number Gender Age Ethnicity
Relation to
patient
with RA
Experience
of testing
Self-reported
musculoskeletal
symptoms
Interview
country
Participant 1 Female 36 White
British
Daughter None None UK
Participant 2 Female 42 White
British
Daughter None Previous septic arthritis UK
Participant 3 Male 35 White
British
Son None None UK
Participant 4 Male 67 White
British
Brother None None UK
Participant 5 Male 31 White
British
Son Reports having had a
‘genetic test’ for RA
(performed by family
physician)
None UK
Participant 6 Female 23 White
British
Daughter None None UK
Participant 7 Female 30 White
British
Daughter None Ankle pain and intermittent
ankle swelling attributed by
patient to a previous ‘ankle
dislocation’
UK
Participant 8 Female 39 White
British
Daughter Rheumatoid factor
previously measured
Elbow pain UK
Participant 9 Female 54 White
British
Sister None Finger pain UK
Participant 10 Female 35 White
British
Daughter None ‘Inflamed knee’ during
pregnancy
UK
Participant 11 Female 44 White
British
Sister and
daughter
None Back pain UK
Participant 12 Female 44 White
British
Sister None Finger pain UK
Participant 13 Female 41 White
British
Sister and
daughter
Rheumatoid factor
previously measured
by family physician
Finger pain, stiffness and
swelling
UK
Participant 14 Female 60 White Daughter Has had ‘blood tests’
(participant unsure
which)
Has a diagnosis of
osteoarthritis
UK
Participant 15 Female 29 White
British
Daughter None None UK
Participant 16 Female 40 White
British
Daughter None None UK
Participant 17 Female 41 Asian
(UK born)
Daughter None None UK
Participant 18 Female 28 White
British
Daughter None None UK
Participant 19 Male 42 Chinese Son None None UK
Participant 20 Female 25 White
British
Daughter None None UK
Participant 21 Female 41 White
British
Daughter None Had previous joint swelling in
wrists and hands
UK
Participant 22 Female 32 White
British
Sister None None UK
Participant 23 Female 44 White
British
Daughter None None UK
Participant 24 Male 47 White
British
Son None None UK
Participant 25 Female 29 White
German
Daughter None None Germany
Participant 26 Female 37 White
German
Daughter None None Germany
Continued
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information related to their actual risk would be of value
to them, allowing them to ‘mentally’ prepare for the
future (Q23). Others could see the beneﬁt of preparing
for the functional limitations that may be associated with
RA (Q24). A few had already undertaken predictive
testing to explore their personal risk of developing RA
(Q25). Some were willing to be tested for altruistic
reasons such as taking part in research (Q26).
Table 1 Continued
Participant
number Gender Age Ethnicity
Relation to
patient
with RA
Experience
of testing
Self-reported
musculoskeletal
symptoms
Interview
country
Participant 27 Female 51 White
German
Daughter None None Germany
Participant 28 Female 21 White
Austrian
Daughter None None Austria
Participant 29 Male 33 White
Austrian
Son None None Austria
Participant 30 Female 65 White
Austrian
Sister None None Austria
Participant 31 Female 36 White
Austrian
Sister Reports having had a
blood test
None Austria
Participant 32 Male 37 White
Austrian
Son None None Austria
Participant 33 Male 37 White
Austrian
Son None None Austria
Participant 34 Female 33 White
Austrian
Daughter None None Austria
RA, rheumatoid arthritis.
Table 2 Quotations related to an understanding of family history and genetic factors as risk factors for rheumatoid arthritis
Code Quotation
Q1 I see that my mother has it and I’m just worried that it might be passed on to me or my sister or other members of my
family. (Participant 19)
Q2 In my opinion it’s environmental factors or genetics. (Participant 28)
Q3 So I know it’s blood-related…I think if it was your cousin or your aunt there’d be a slim chance…being direct
blood-related, I would class myself as, or think of myself that I am at a higher risk than most. (Participant 6)
Q4 I seem to follow my mum in absolutely everything, like my brother and sister they’re quite like my dad, they never get
ill, they never catch a cold. Whereas if there’s a cold going around I will get it and the same with my mum…So I was a
bit like ‘oh, maybe I’ll get it’. (Participant 18)
Q5 I know that there’s a genetic tendency. That it runs in families. I’m female, so I’m more at risk because I’m female…I
know first degree relative increases your risk, so yeah, it does worry me. (Participant 10)
Q6 Genetics really worry me because I don’t know anything about them and I think when people think of genetics they
think of like I don’t know it’s quite like a complicated thing that we’re never going to understand because there’s no
simple way of putting it…But like your average Joe Bloggs [average person] isn’t going to know extensive information
about your genes. (Participant 20)
Q7 For me personally it’s kind of hard facts and figures; I’m more comfortable knowing in terms of percentages. I know
my dad has got rheumatoid arthritis, and if you’ve got a hard fact and figure to say that the chances of a close relative,
son or daughter, developing rheumatoid arthritis at some point in their life then that information would be useful to me.
(Participant 5)
Q8 It [life] wouldn’t be predictable anymore; I wouldn’t know how things would be from one day to the next, or in an hour’s
time, when I woke up the next morning, wondering what the day would bring. I think it’s pretty serious, it restricts your
everyday life. And it differs—my father has pain and sometimes it’s there, sometimes it’s not; it’s unpredictable.
(Participant 25)
Q9 I do worry about it, yeah, because I don’t want to end up developing anything like that. I like to keep busy and I don’t
want to be restricted. It is a big worry, yeah. I don’t want to go through what my mum’s going through at the moment,
because she’s been through a lot. (Participant 13)
Q10 I’ve got pain down my left leg [okay], but I just don’t know whether it’s sciatica, or whether it could be something
linked to arthritis, but I’m too frightened to go and have a scan. So I probably do need it to find that. I’m just putting it
off. (Participant 15)
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Perceptions surrounding the use of predictive tests:
negative perspectives
The ability of predictive tests to quantify risk was widely
discussed (Q27), with one participant questioning the
speciﬁcity and sensitivity of the test (Q28). Relatives
expressed a desire for tests that would, with a very high
likelihood, be able to conﬁrm or exclude the fact that
they would develop RA (Q29). However, many relatives
suspected that test results would give them an intermedi-
ate risk of developing RA and others highlighted con-
cerns about ‘false-positive’ results (Q30). Some believed
that predictive testing would not be able to give them
answers to questions they thought were important, for
example, how severe would their RA be were they to
develop it, and when it would be most likely to begin
(Q31).
Relatives were worried about the impact of testing on
their family members and in particular on their sibling/
parent with RA (Q32). Participants felt that seeking
information about risk and pursuing testing would cause
their relative with RA to experience stress, worry or feel-
ings of guilt. Participants were further worried about the
stress that predictive test results may cause them. One
even suggested that such stress could cause the disease
to develop earlier than it otherwise would (Q33).
Relatives felt that being given risk information when
they were young would be a particular burden (Q34).
Instead, they felt that testing should be left until later in
life, when the chance of developing a condition like RA
was higher. Risk information was considered to have sig-
niﬁcant implications for future life choices and could
make them ‘rush’ through life (Q35). One relative
Table 3 Quotation related to personal considerations of rheumatoid arthritis risk and communication about risk within
families
Code Quotation
Q11 That’s exactly what he doesn’t talk to me about, he’s the kind of person who leaves others out of it, deals with it by
himself. (Participant 30)
Q12 I am worried about that…I was quite surprised when mum said that she’d had this letter explaining about the research
that you’re doing. (Participant 23)
Q13 He doesn’t tend to talk about it. He didn’t want to ask me to do this phone call, but forced himself to one day…This is
probably the first time he’s actually asked me to do anything and he was clearly uncomfortable. (Participant 24)
Q14 I never had that information of what happens, how you’re made at higher risk, I’ve never had that in like black and
white…which makes me think she doesn’t know or maybe she’s just trying to protect me like a mother does. Because
I think she was quite worried about me taking part…she’s quite worried about what I’d find out. (Participant 5)
Q15 My mum, sort of, mentioned this to him [brother], and he was just, like, ignored the fact that she’d said anything to me.
And then she came to me and said, ‘I thought I’d ask your brother first but he won’t,’ and I said, ‘I don’t mind,’ but he’s
probably different to me, just blissful ignorance, whereas I’m probably a little bit different. (Participant 2)
Q16 Up until now I have never thought about it, what that would be like, whether it might happen. (Participant 28)
Q17 I guess before we spoke I couldn’t understand what it was exactly that was making her finger sore or swollen or
anything like that. I would just be like, drink more milk. (Participant 20)
Q18 You only worry too much and rack your brain, because then I have to consider that my children could get it too and
then you would worry too much. It’s more comfortable to avoid it. (Participant 32)
Table 4 Quotations related to perceptions surrounding the use of predictive tests: positive perspectives
Code Quotation
Q19 I’m open to everything, well, I don’t know why I shouldn’t have that done, I couldn’t think of a reason off the top of my
head not to do it. (Participant 31)
Q20 If I was offered a test, I’d be very happy to have one. I don’t need to think about that. Well, it might be if it might help
me combat a disease later, or at least know how to treat it. Well, if I’m at risk I think it would be helpful to know.
(Participant 3)
Q21 I would do that straight away, because I want to know as soon as possible, because I think the more you know the
earlier, the more you can do about it. (Participant 31)
Q22 I think that with kind of information, I’d be more keen to, sort of, sort out what I needed to do to try and prevent that
becoming a problem. If I could take some sort of medication to…head it off before it became a big problem.
(Participant 2)
Q23 I think that would be a good thing. I think I’d like to know because then I may be able to prepare a bit more, like
mentally as well. (Participant 20)
Q24 Yes, it would. I think I would have the test just to see what the long-term forecast is, because my job’s fairly labour
intensive. I’d be willing to know what the future holds, just from the point of view of my job circumstances at work.
(Participant 19)
Q25 Actually I did get tested, but it was a long time ago. (Participant 27)
Q26 I’m not averse to having them, especially, if it helps with research and stuff like that. (Participant 2)
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suggested that such information could bring forward
major life decisions, such as having children (Q36).
Some relatives reﬂected on previous negative personal
experiences of having received poorly communicated
test-related information (Q37). For some, the approach
to the delivery of risk information represented an
important feature of a predictive test and may determine
whether the test would be acceptable to them. Relatives
discussed how they would want to be told prior to the
test what format the result would take. Some suggested
that they would like to receive the results by letter, and
then be given the opportunity to discuss the results with
a healthcare professional (Q38). Other relatives empha-
sised the importance of talking to someone about the
Table 5 Quotations related to perceptions surrounding the use of predictive tests: negative perspectives
Code Quotation
Q27 Exactly, if it is only a vague presumption where they say, yes, you could perhaps out of two to five people or
something, you could get it and the others wouldn’t, well that is very vague. (Participant 32)
Q28 That depends on the test, how specified it is and how sensitive it is, otherwise I would not have the test done.
(Participant 29)
Q29 Because if told me—it’s only how likely, it’s not a, ‘You will develop it,’ and it doesn’t tell you when you will develop it.
So I think if somebody said to me, ‘There’s this test out there and it’ll tell you whether you might develop it,’ I wouldn’t
want it, because you could just live your life in fear and never actually develop it. So unless it was 100% guaranteed,
and somebody could say, ‘You will develop it within this time frame,’ I don’t wanna [want to] spend the next 30 years
worrying about something, when I could be enjoying those 30 years. So, no, I’d probably—it depends on the exact
details of the test. (Participant 10)
Q30 Or, equally, I guess, false positive. If you’ve got one really bad, sort of, joint that you’ve tested, it could, kind of, put a
bit of a negative spin on it. (Participant 1)
Q31 It would be nice to know when…at what point in time you were going to get ill, and how severe it was going to be…
but I don’t know whether a test can find that out. (Participant 25)
Q32 But I wouldn’t want to worry my mum by saying, can you get me a leaflet on testing. I wouldn’t want my mum to worry
that I was going for this test…to know that if in five years time I’ll get it, I don’t want her to know that because I think
that would worry her more than anything. (Participant 6)
Q33 On the one hand you know that you might develop the disease and it is of course stressful, because then you know,
one day, when I’m about 30–40 years old, it will start and then my body will become weaker and I will get this
disease, then it could create a lot of stress to have these negative thoughts. I don’t know what the psychological effect
would be on the body, whether it really might break out sooner. If you don’t know, so, if you say, I don’t know and you
live each day as it comes, meaning that it might break out at a later date. (Participant 32)
Q34 From personal experience, I think it would be something that when I got a bit older and certain things started going
wrong with me or I started getting more illnesses I’d think I’d need to start looking to what all these problems are. At
this particular moment in time, when there’s generally nothing wrong with me, I just think that I don’t really need to
delve too much into that sort of information. (Participant 4)
Q35 Yeah I kind of wouldn’t want this test to tell me that I had a 50/50 chance of getting it in the next five years because
that would change my entire perception on what I wanted. And I guess if someone gave me that bit of information I’d
have to seriously think, well maybe I can’t have that, maybe I’ve got to like push everything forward like get married
and have kids before I start to take medication which I guess that’s a lot of information I don’t know about in that if I
had to start taking that medication would that affect me having kids. It’s like knowing when you’re going to die that
doesn’t sit right with me either. (Participant 15)
Q36 I think, if, for argument’s sake, I’d gone for the test tomorrow, and the results came back and they said, ‘Yeah, you’re
at high risk,’ and in two years’ time, the symptoms kicked in, you’re then thinking, ‘Right, okay.’ We’d probably want a
second child and we’d want a third, ‘Let’s do it now,’ sort of, thing, but otherwise, I think, you know, just life would
carry on (Participant 6).
Q37 The GP [family physician] literally just sat me down, blurted some technical words out, medical terminology to me that
went straight over my head and, again, didn’t sink. I think, just keep simple, instead of baffling people with medical
science, really, of your technical words that you use, compared to what, sort of, the general public are going to
understand. (Participant 6)
Q38 I’d be happy, I think, if, before the test, someone would explain the kind of outcome to expect. And then when I got
the test results back, it would be okay by post, as long as there was, kind of, accompanying information. I suppose at
that point you’d probably end up going to see someone anyway to talk through what tablets or whatever you could
take. (Participant 1)
Q39 I suppose it would be sensible to go and talk to somebody about it. (Participant 3)
Q40 I think it’s a good idea to talk to somebody and find out more information. I think seeing somebody on a regular basis,
like every year or something, might be good if you knew that you were going to get it. Obviously, you’re going to have
more and more questions, aren’t you? Yeah, for an update and just to see how things are going. Obviously, as time
goes on, you’re going to have more questions and so I think it would be good to speak to somebody. (Participant 20)
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test result, especially to manage the psychological dis-
tress that may be associated with receiving a ‘positive’
test result (Q39). Many relatives felt that there was a
need for ongoing support from a healthcare profes-
sional following testing (Q40).
DISCUSSION
This study explored the degree to which ﬁrst-degree
relatives of people with RA felt that they were susceptible
to developing RA and their perceptions of predictive
testing. Most relatives were aware that there was a
genetic contribution to the risk of RA and that they may
be susceptible to developing RA; however, they were
unsure of the extent of the additional risk. Relatives
highlighted the need for additional information about
familial risk and described the need for better commu-
nication strategies in relation to imparting this
information.
Generally, ﬁrst-degree relatives felt that there was a
need for more information and support speciﬁcally
designed for the family members of people with RA.
The current lack of support and information was sug-
gested to have a number of effects, including family
members not feeling able to communicate and support
the person affected with RA and not feeling able to
understand concepts surrounding the nature of RA and
the risks associated with RA. Studies of information
sharing among family members at risk of cancer have
found that patients with the disease do not always com-
municate risk information in a timely or thorough
fashion.41 Forrest et al42 found that relatives from smaller
families, and female relatives, were more likely to make
contact with genetic services. Research has shown that
genetic counselling can facilitate interfamily communi-
cation and can help to minimise distress and increase
the number of family members making contact with
health services to be tested.43 44
An incidental ﬁnding of this research was that being
invited to take part in research about risk was the ﬁrst
time that some relatives had fully considered their per-
sonal susceptibility to RA. In some cases, this exposure
was viewed positively, but in other cases, it caused worry
and concern. It is difﬁcult to draw conclusions about the
speciﬁc impact taking part in this study had on relatives’
well-being, but we note that relatives did indicate that
support mechanisms would be helpful to enable them
to understand and cope with risk-related information,
especially if predictive testing were to be offered. We
would suggest that researchers accessing participants in
‘at-risk’ populations pay particular attention to the
impact that an invitation to participate and participation
itself may have, and offer additional support to, mitigate
against anxiety caused. While personal susceptibility may
not have been considered, perceptions of RA severity
may predict personal willingness to engage in predictive
testing. It is possible that ﬁrst-degree relatives of people
with more severe forms of RA or poorly controlled
disease maybe more motivated to engage in predictive
testing. This would be in line with the predictions of the
health belief model.45 A quantitative investigation to
assess the effect of factors such as disease severity in
people with RA, on their family members’ perceptions
of risk and orientation towards predictive testing, is
needed to test this hypothesis.
In addition, it became apparent during the course of
this study that some relatives were symptomatic but had
not yet sought medical help. Detailed information on
the health status of the participating relatives was not
gathered within this study, but those who were symptom-
atic were advised to speak to their family physician and
were given details of resources for obtaining additional
information. However, the symptomatic nature of some
relatives raises important issues surrounding informing
relatives about risk, and the importance of seeking help
quickly should symptoms emerge. While some relatives
were aware that their symptoms may be indicative of the
early stages of RA, and were worried about what infor-
mation would be revealed to them if they sought help,
few were aware of the importance of early intervention.
Where information about the beneﬁts of early interven-
tion in preventing joint destruction made available to
them, it is possible that their attitude to help-seeking
may have been different.
This study has a number of limitations. First, our
access to ﬁrst-degree relatives was via patients with RA.
Some relatives described how they were chosen in pref-
erence to other relatives, who would either worry too
much or not be receptive to discussing issues related to
risk. The ﬁndings presented may thus not fully reﬂect
the range of views related to risk and testing held by
ﬁrst-degree relatives. This potential limitation highlights
the need to fully understand the barriers that patients
with RA face when discussing issues of risk with family
members. A second limitation of this research was that
the majority of participants were women. A criticism of
many qualitative studies in the ﬁeld of RA is that the
male perspective is under-represented.8 While the
female:male ratio of RA is typically 2:1, it is essential that
studies attempt to include the views of more male parti-
cipants. Therefore, we acknowledge that themes related
to gender and male perspectives of risk and predictive
testing did not reach saturation and are not represented
in our data. A ﬁnal limitation is that only a small
number of individuals from ethnic-minority communi-
ties were interviewed; therefore, a full understanding of
the cultural barriers to predictive testing was not
achieved.
Besides these limitations, this study has a number of
strengths. Relatives were sampled from centres in three
different European countries and saturation of the main
themes was achieved by combining interview data from
all centres; furthermore, no differences in the views
expressed by relatives sampled from different European
countries were detected. Gathering data from multiple
countries means that interventions developed based on
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these data are likely to be relevant in multiple contexts.
A further strength of this study was the support given by
an international panel of patient research partners who
advised researchers and acted as coresearchers.
Identifying individuals at risk of RA may allow targeted
interventions to reduce the risk and consequence of
future disease; however, our data show that relatives have
concerns about predictive testing and risk information
that would result from it (the key messages of this study
are summarised in box 2). The future development of
strategies to quantify and communicate risk needs to
take these views into account and incorporate
approaches to mitigate concerns and minimise any nega-
tive psychological impact of risk information.
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